Login to Your Account



Deals And M&A NEWS
Merck & Co. Inc. turned to a small Israeli biotech, Ccam Biotherapeutics Ltd., to pad its immuno-oncology (I-O) pipeline with a next-generation monoclonal antibody (MAb) targeting the immune checkpoint protein known as carcinoembryonic antigen-related cell adhesion molecule 1, or CEACAM1.
HONG KONG – Newly listed Chinese biopharmaceutical company Shenyang-based 3SBio Inc. acquired small-molecule maker Zhejiang Wansheng Pharmaceutical Co. Ltd. for ¥528 million (US$85 million) to complement its oncology and nephrology pipeline.

SHANGHAI – Phagelux Inc., a Shanghai-based company developing bacteriophages for both human and animal use, has acquired Omnilytics Inc. 

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: